ArticleScientific reports2025
Integrative analysis identifies shared therapeutic pathways in thyroid eye disease and diabetes mellitus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid eye disease (TED) and diabetes mellitus (DM) cause vision loss, with DM aggravating TED. In this study, we aimed to explore the mechanisms of this interaction, and therefore, analyzed gene expression data from representative TED and DM datasets using bioinformatic tools. Following normalization and differential expression analysis, common differentially expressed genes (CDEGs) between the datasets were identified and subjected to Gene Set Enrichment Analysis (GSEA), as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses. Interaction networks were constructed and the diagnostic potential of the CDEGs was assessed using receiver operating characteristic (ROC) curve analysis. The TED_Dataset and DM_Dataset contained 449 and 108 DEGs, respectively, with seven CDEGs. GO and KEGG analyses linked the CDEGs to biological processes including leukocyte adhesion and apoptosis. GSEA emphasized their roles in inflammation and fibrosis. Protein-protein interaction network analysis identified MFAP4 as a key hub gene. Constructed mRNA-transcription factor, mRNA-RNA binding protein, mRNA-microRNA, and mRNA-drug interaction networks revealed extensive regulatory relationships. ROC curve analysis demonstrated that CXCL12 and SFRP4 were potential diagnostic biomarkers for TED, and SFRP4, IL6, MFAP4, and CRISPLD2 were potential diagnostic biomarkers for DM. Altogether, our findings provide comprehensive molecular insights into DM and TED, identifying novel targets for therapeutic intervention and diagnostic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.